Glycomimetics, Inc.

Other

Glycotech Corp.

Novartis Ag

The General Hospital Corporation

Crescent Biopharma, Inc.

John L Magnani

Arun K Sarkar

John Tinsman Patton, Jr

Myung-Gi Baek

John M Peterson

Beat Ernst

Frank Elbert Anderson, Iii

Yanhong Li

Eugene C Butcher

Ellen L Berg

Sergei A Svarovsky

Leonard M Williams

Yusufbhai U Vohra

William E Fogler

Indranath Ghosh

Yusuf U Vohra

Jason Nogueira

Eric G Bremer

Rudolf Duthaler

Gebhard Thoma

John T Patton

Matthias P Nahrendorf

Theodore A G Smith

Hong-Woon Yang

Daniel Schwizer

Frank E Iii Anderson

Iii Anderson Frank E

Theodore AG Smith

Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.

E-selectin antagonist compounds, compositions, and methods of use

Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, E-selectin antagonists are described and pharmaceutical compositions comprising at least one of the same.

Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists

Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed. For example, inhibitors of galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.

Galectin-3 inhibiting c-glycosides

Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands are disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.

Heterobifunctional inhibitors of E-selectin and galectin-3

Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, highly potent multimeric E-selectin antagonist are desorbed and pharmaceutical compositions comprising at least one of the same.

Highly potent multimeric e-selectin antagonists

Methods are disclosed for the mobilization of marrow infiltrating cells (MILs) using E-selectin antagonists for the treatment of disorders such as cancer. Methods for treating or preventing cancers using MILs mobilized by E-selectin antagonists are further disclosed.

Methods of mobilizing marrow infiltrating lymphocytes and uses thereof

Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands a disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described. 

Compositions and methods for the treatment of diseases, disorders, and/or conditions associated with the increased regulatory T lymphocyte cell function, comprising the administration of T-cell checkpoint inhibitors in combination with E-selectin inhibitors, C&#x2014;X&#x2014;C Motif Chemokine Receptor 4 (CXCR4) receptor inhibitors, and/or heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, are disclosed.

Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4

New methods for treating and/or preventing cardiovascular disease including, for example, myocardial infarction and atherosclerosis, by the use of at least one E-selectin inhibitor and compositions comprising the same are disclosed.

Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin

Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists

Compounds, compositions, and methods for the diagnosis and/or treatment of medical conditions involving infections with and colonization bybacteria including, for example,in the lungs of patients with cystic fibrosis are described.

Glycomimetic inhibitors of PA-IL and PA-IIL lectins

Growing community of inventors

Gaithersburg, MD, United States of America

John L Magnani